While the BCR–ABL fusion gene plays an important role in the initial stages of CML, some patients were suffered from the progression of CML because of the TKI intolerance or drug resistance. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.